Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to ...
On October 27, Thermo Fisher Scientific and Lundbeck both announced new collaborations with OpenAI. These moves represent a continuing trend of drug development companies inking deals with technology ...
In today’s ACT Brief, we examine how artificial intelligence is helping uncover site leaders in underserved regions to strengthen trial diversity—and explore new research suggesting Ozempic may reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback